TNFi Therapy Research Articles

AB0541 Factors associated with selection of rituximab vs alternative TNF inhibitor (TNFI) following TNFI failure in patients with rheumatoid arthritis: Sub-analysis of switch-RA, a global, comparative effectiveness observational study

BackgroundSWITCH-RA is a global observational study evaluating the effectiveness of switching to an alternative TNFi or to rituximab (RTX) following initial TNFi failure in patients with RA. This subanalysis assessed...

SAT0301 A comparative analysis of PSA spondylitis patients with PSA and AS 12 months after initiation of TNFI therapy

BackgroundSpondyloarthropathies (SpA) are a family of disorders with common characteristics. This study compares baseline data and clinical outcomes 12 months post-TNFi therapy in patients with PsA plus spondylitis (PsAs), psoriatic...

THU0248 Patient-Oriented Decision of Early Treatment of Rheumatoid Arthritis with Combination of Triple Conventional Disease Modifying Anti-Rheumatic Drugs or Tumor Necrosis Factor Inhibitors and Methotrexate (Prospective, Open-Label Clinical Trial)

BackgroundEarly optimization of conventional disease modifying anti-rheumatic drugs (cDMARD) treatment is imperative as delay of biologics in certain patients can lead to irreversible functional disability. Bucillamine (BUC) is a unique...

SAT0046 Should there be Different Disease Activity Criteria for Assessment of Patients with Rheumatoid Arthritis According to Ethnic Backgrounds?

BackgroundPrevious studies on RA features between different ethnic groups have mainly focused on disability and disease activity scores, structural damage, genetic factors and health inequalities. However, data on RA distribution...

AB0586 Role of particular class i mhc genotypes and haplotypes in determining different traits within the psoriatic arthritis phenotypes

BackgroundA rigorously ascertained psoriatic arthritis (PsA) cohort demonstrated considerable genetic heterogeneity and provided preliminary evidence that MHC genes determine quantitative traits within the PsA phenotype with different patterns of MHC...

FRI0332 Etanercept therapy in patients with refractory behcet’s disease: uveitis and beyond.

BackgroundBehcet’s disease (BD) is a chronic relapsing multisystem inflammatory where Tumor necrosis factor alpha is believed to play a pivotal role.[1-3]ObjectivesInvestigate the benefit of one year treatment with etanercept, a...

SP0147 Non-anti-TNF biologics in PSA

Despite the substantial benefit of TNFi therapy for psoriatic arthritis, as demonstrated in clinical trials and in over a decade of clinical use globally, there remains an unmet medical need...

TNF-inhibitor drugs regulate human pathogenic Th17 cells through induction of IL-10

Results Ex vivo analysis of patients with RA on TNFi therapy revealed an enrichment of Th17 cells in peripheral blood compared to those on disease-modifying anti-rheumatic drugs or healthy controls. However, we also found an increase in IL-10-producing CD4+ T-cells. The enrichment in IL-17+ and IL-10+ CD4+ T-cells, including IL17+IL-10+ co-expressing CD4+ T-cells, was recapitulated in vitro by the addition of TNFi drugs (adalimumab, infliximab, etanercept, and certolizumab) to human monocyte/CD4+ T-cell co-cultures. IL-10 induction was independent of FcgR binding, IL-10 and CD4+CD25+ Tregs. TNFi-induced Th17 cells were functionally distinct as shown by an ability to modulate CD14+ monocytes in an IL-10-dependent manner. We report the identification of a transcription factor that is strongly associated with IL-10 expression in TNFi-induced IL-17+ CD4+ T-cells, and show that overexpression of this transcription factor drives IL-10 expression in primary CD4+ T-cells.